Cytek Biosciences Inc
NASDAQ:CTKB

Watchlist Manager
Cytek Biosciences Inc Logo
Cytek Biosciences Inc
NASDAQ:CTKB
Watchlist
Price: 4.95 USD 3.13% Market Closed
Market Cap: 632.9m USD

Wall Street
Price Targets

CTKB Price Targets Summary
Cytek Biosciences Inc

Wall Street analysts forecast CTKB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTKB is 5.87 USD with a low forecast of 4.04 USD and a high forecast of 7.88 USD.

Lowest
Price Target
4.04 USD
18% Downside
Average
Price Target
5.87 USD
18% Upside
Highest
Price Target
7.88 USD
59% Upside
Cytek Biosciences Inc Competitors:
Price Targets
688222
HitGen Inc
14% Upside
688046
GemPharmatech Co Ltd
37% Upside
DIM
Sartorius Stedim Biotech SA
18% Upside
SHC
Sotera Health Co
12% Upside
A
Agilent Technologies Inc
24% Upside
SFZN
Siegfried Holding AG
52% Upside
CGEN
Compugen Ltd
319% Upside
DHR
Danaher Corp
16% Upside

Revenue
Forecast

Revenue Estimate
Cytek Biosciences Inc

For the last 4 years the compound annual growth rate for Cytek Biosciences Inc's revenue is 21%. The projected CAGR for the next 4 years is 6%.

21%
Past Growth
6%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Cytek Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

Net Income Estimate
Cytek Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-32%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CTKB's stock price target?
Price Target
5.87 USD

According to Wall Street analysts, the average 1-year price target for CTKB is 5.87 USD with a low forecast of 4.04 USD and a high forecast of 7.88 USD.

What is Cytek Biosciences Inc's Revenue forecast?
Projected CAGR
6%

For the last 4 years the compound annual growth rate for Cytek Biosciences Inc's revenue is 21%. The projected CAGR for the next 4 years is 6%.

Back to Top